Drinking coffee may have more profound survival benefits for patients with HIV and hepatitis C than for the general population.
Hepatitis/MASH
Latest News
Advertisement
CME Content
Advertisement
Researchers continue to focus on developing an 8-week treatment regimen for hepatitis C virus.
Top news of the day from across the healthcare landscape.
Top news of the day from across the healthcare landscape.
A look at the top stories in pharmacy last week.
A look at the top stories in pharmacy last week.
Top news from across the healthcare landscape.
Top news from across the healthcare landscape.
Top news of the week from Specialty Pharmacy Times.
National brand spending and new patient rates for hepatitis C virus dropped last year.
The pharma giant will now focus on its PD-1 cancer immunotherapy Keytruda.
Ramping up programs for injection drug users is a key part in preventing transmission of hepatitis C.
Testing and treatment programs should focus on populations driving new cases of hepatitis C virus.
Trending News Today: Cash Reimbursements Offered to Customers Impacted by Aetna's HIV Privacy Breach
Top news of the day from across the health care landscape.
Recent studies suggested that hepatitis C antiviral drugs may increase the risk of hepatocellular carcinoma.
Top news of the day from across the healthcare landscape.
There are several key therapeutics areas of which to be aware.
Top news of the day from across the health care landscape.
This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection, including elbasvir and grazoprevir (Zepatier).
Top news of the week from Specialty Pharmacy Times.
Promotion of healthy lifestyle changes are crucial among HIV-positive patients cured of hepatitis C.
Top news of the day from across the healthcare landscape.
Coffee drinking can cut down risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) by half, according to a 5-year study published in the Journal of Hepatology.
Same-day results increase the number of individuals who get tested and treated for HCV.
Top news of the week from Specialty Pharmacy Times.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
Why Some Patients Do Not Respond to GLP-1 Therapies
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer, Earning FDA Priority Review
5